GLAXOSMITHKLINE PLC Form 6-K April 17, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 17 April 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company') GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley

Chief Executive Officer

b) Position/status

c) Initial notification/
amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument

each ('Ordinary Shares')

ISIN: GB0009252882

Acquisition of Ordinary Shares following the

b) Nature of the transaction re-inv

re-investment of dividends paid to shareholders on 12

April 2018.

Price(s) Volume(s) £14.3999 1885.380 n/a (single transaction)

Aggregated information

c) Price(s) and volume(s)

d)

Aggregated volume Price

e) Date of the transaction 2018-04-12

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr R G Connor

b) Position/status President, Global

Manufacturing & Supply

c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

Acquisition of Ordinary

Shares following the re-investment of dividends

b) Nature of the transaction re-investment of dividends paid to shareholders on 12

April 2018.

n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

e) Date of the transaction 2018-04-12

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Debruyne

b) Position/status President, Global Vaccines

Initial notification/
Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary

Shares following the re-investment of dividends paid to shareholders on 12

April 2018.

n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

e) Date of the transaction 2018-04-12

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans

b) Position/status Chief Financial Officer

Initial notification/ Initial notification

amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary

Shares following the

b) Nature of the transaction re-investment of dividends

paid to shareholders on 12

April 2018.

Price(s) Volume(s)

£14.3999 1289.846

n/a (single transaction)

Aggregated information

c) Price(s) and volume(s)

d)

Aggregated volume Price

e) Date of the transaction 2018-04-12

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern

b) Position/status Chief Strategy Officer

Initial notification/

Initial notification amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

> Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 a) Description of the financial instrument

Acquisition of Ordinary

Shares following the

re-investment of dividends b) Nature of the transaction

paid to shareholders on 12

April 2018.

Price(s) Volume(s) c) Price(s) and volume(s)

£14.3999 2388.623 n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

e) Date of the transaction 2018-04-12

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Ms C Thomas a) Name SVP. HR b) Position/status

Initial notification/ Initial notification c)

amendment

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence

each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12
	April 2018.

Price(s) Volume(s) c) Price(s) and volume(s) £14.3999 1514.507

n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

e) Date of the transaction 2018-04-12

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Mr P C Thomson a) Name

b) Position/status

President, Global Affairs

Initial notification/ Initial notification amendment

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

> Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

Acquisition of Ordinary

Shares following the re-investment of dividends paid to shareholders on 12

April 2018.

Price(s) Volume(s) c) Price(s) and volume(s) £14.3999 1262.984

d) Aggregated information n/a (single transaction)

Aggregated volume Price

b) Nature of the transaction

e) Date of the transaction 2018-04-12

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mrs K Thomson

b) Position/status

PCA of Mr P C Thomson
(President, Global Affairs)

Initial notification/
Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

a) Description of the financial instrument each ('Ordinary Shares') ISIN: GB0009252882

3HV. GD0009232002

Acquisition of Ordinary Shares following the

b) Nature of the transaction re-investment of dividends

paid to shareholders on 12

April 2018.

c) Price(s) and volume(s) Price(s) Volume(s) £14.3999 156.475

n/a (single transaction)

Aggregated information

d)

Aggregated volume Price

e) Date of the transaction 2018-04-12

Place of the transaction London Stock Exchange

(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons

b) Position/status SVP, Global Ethics and

Compliance

c) Initial notification/ Initial notification

amendment

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

each ('Ordinary Shares')

ISIN: GB0009252882

Acquisition of Ordinary

Shares following the

re-investment of dividends

paid to shareholders on 12

April 2018.

Price(s) Volume(s) £14.3999 380.094

n/a (single transaction)

Aggregated information

b) Nature of the transaction

c) Price(s) and volume(s)

a) Description of the financial instrument

d)

Aggregated volume Price

e) Date of the transaction 2018-04-12

Place of the transaction London Stock Exchange

(XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: April 17, 2018

By: VICTORIA WHYTE-

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc